These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 28925748)

  • 1. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
    Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
    Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lomitapide for the management of homozygous familial hypercholesterolemia.
    deGoma EM
    Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
    Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
    Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
    Perry CM
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Bruckert E; Kalmykova O; Bittar R; Carreau V; Béliard S; Saheb S; Rosenbaum D; Bonnefont-Rousselot D; Thomas D; Emery C; Khoshnood B; Carrié A
    Atherosclerosis; 2017 Feb; 257():130-137. PubMed ID: 28131047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.
    Won JI; Zhang J; Tecson KM; McCullough PA
    Rev Cardiovasc Med; 2017; 18(1):21-28. PubMed ID: 28509890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
    Stefanutti C
    Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
    Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 12. Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia.
    Blom DJ; Cuchel M; Ager M; Phillips H
    Orphanet J Rare Dis; 2018 Jun; 13(1):96. PubMed ID: 29925433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child.
    Chacra APM; Ferrari MC; Rocha VZ; Santos RD
    J Clin Lipidol; 2019; 13(3):397-401. PubMed ID: 30948303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience.
    Sperlongano S; Gragnano F; Natale F; D'Erasmo L; Concilio C; Cesaro A; Golia E; Crisci M; Sperlongano R; Fimiani F; Russo M; Arca M; Limongelli G; Calabrò P
    J Cardiovasc Med (Hagerstown); 2018 Mar; 19(3):83-90. PubMed ID: 29389816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
    Cuchel M; Blom DJ; Averna MR
    Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.
    Averna M; Cefalù AB; Stefanutti C; Di Giacomo S; Sirtori CR; Vigna G
    Nutr Metab Cardiovasc Dis; 2016 Jan; 26(1):36-44. PubMed ID: 26723464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.
    Toth PP; Shah PK; Wilkinson MJ; Davidson MH; McCullough PA
    Rev Cardiovasc Med; 2014; 15(1):1-10. PubMed ID: 24762461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.
    Cuchel M; Meagher EA; du Toit Theron H; Blom DJ; Marais AD; Hegele RA; Averna MR; Sirtori CR; Shah PK; Gaudet D; Stefanutti C; Vigna GB; Du Plessis AM; Propert KJ; Sasiela WJ; Bloedon LT; Rader DJ;
    Lancet; 2013 Jan; 381(9860):40-6. PubMed ID: 23122768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design.
    Blom DJ; Fayad ZA; Kastelein JJ; Larrey D; Makris L; Schwamlein C; Bloeden L; Underberg J;
    J Clin Lipidol; 2016; 10(2):273-82. PubMed ID: 27055957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.
    Roeters van Lennep J; Averna M; Alonso R
    J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.